TGTX Financial Statements From 2010 to 2024

TGTX Stock  USD 13.99  0.17  1.23%   
TG Therapeutics financial statements provide useful quarterly and yearly information to potential TG Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on TG Therapeutics financial statements helps investors assess TG Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting TG Therapeutics' valuation are summarized below:
Gross Profit
2.5 M
Profit Margin
0.0542
Market Capitalization
2.2 B
Enterprise Value Revenue
8.9013
Revenue
233.7 M
We have found one hundred twenty available fundamental measures for TG Therapeutics, which can be analyzed and compared to other ratios and to its peers in the sector. All investors should make sure to double-check all of TG Therapeutics latest market performance against the performance between 2010 and 2024 to make sure the company can sustain itself this quarter and beyond. Market Cap is likely to rise to about 2.5 B in 2024. Enterprise Value is likely to rise to about 2.6 B in 2024

TG Therapeutics Total Revenue

245.35 Million

Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TGTX main balance sheet or income statement drivers, such as Depreciation And Amortization of 433.5 K, Interest Expense of 13.2 M or Total Revenue of 245.3 M, as well as many exotic indicators such as Price To Sales Ratio of 9.86, Dividend Yield of 4.0E-4 or PTB Ratio of 15.86. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
This module can also supplement TG Therapeutics' financial leverage analysis and stock options assessment as well as various TG Therapeutics Technical models . Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

TG Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets346.1 M329.6 M170.8 M
Slightly volatile
Other Current Liabilities7.2 M13.5 M11.3 M
Slightly volatile
Total Current Liabilities56.4 M53.7 M34 M
Slightly volatile
Property Plant And Equipment Net8.6 M8.1 M4.7 M
Slightly volatile
Cash59.3 M92.9 M101.5 M
Slightly volatile
Non Current Assets Total7.5 M11.6 M11.8 M
Slightly volatile
Cash And Short Term Investments228.4 M217.5 M144.7 M
Slightly volatile
Common Stock Shares Outstanding155.9 M148.5 M72.2 M
Slightly volatile
Total Liabilities177.5 M169.1 M88.5 M
Slightly volatile
Property Plant And Equipment Gross10 M9.6 M4.9 M
Slightly volatile
Total Current Assets333.8 M317.9 M158.7 M
Slightly volatile
Other Current Assets10 M9.5 M2.2 M
Slightly volatile
Common Stock Total Equity74.7 K131.4 K126.9 K
Slightly volatile
Common Stock105.2 K151 K130.2 K
Pretty Stable
Short and Long Term Debt Total116.3 M110.8 M32.2 M
Slightly volatile
Other Liabilities260.8 K274.5 K2.5 M
Very volatile
Short Term Debt2.6 M1.4 M2.4 M
Pretty Stable
Current Deferred Revenue285 K300 K3.4 M
Pretty Stable
Intangible Assets684 K720 K2.4 M
Slightly volatile
Net Tangible Assets118.5 M66.5 M99.2 M
Slightly volatile
Good Will864.8 K918.9 K789 K
Slightly volatile
Long Term Debt Total85.9 M81.8 M33.2 M
Slightly volatile
Capital Surpluse1.9 B1.8 B729.8 M
Slightly volatile
Short and Long Term Debt1.1 M1.1 M1.9 M
Pretty Stable
Net Invested Capital220.5 M260.6 M139.6 M
Slightly volatile
Net Working Capital210.5 M264.2 M133.8 M
Slightly volatile
Capital Stock141.9 K151 K105.9 K
Slightly volatile
Non Current Liabilities Other9.5 M9.3 M15 M
Slightly volatile
Capital Lease Obligations9.2 M10.7 M11.6 M
Slightly volatile

TG Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization433.5 K423 K690.8 K
Slightly volatile
Other Operating Expenses223.7 M213 M131.3 M
Slightly volatile
Research Development45.7 M76.2 M77.3 M
Slightly volatile
Total Operating Expenses208.4 M198.5 M129.2 M
Slightly volatile
Selling General Administrative142.5 M135.7 M82.8 M
Very volatile
Non Operating Income Net Other1.1 M2.1 M1.5 M
Pretty Stable
Interest Income6.4 M6.1 M2.4 M
Slightly volatile
Reconciled Depreciation321.6 K423 K196.3 K
Slightly volatile

TG Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow56.1 M102.3 M95.7 M
Slightly volatile
End Period Cash Flow59.5 M92.9 M102 M
Slightly volatile
Stock Based Compensation19.1 M37.9 M20.8 M
Slightly volatile
Change To Netincome23 M21.9 M19.7 M
Slightly volatile
Issuance Of Capital Stock39.6 M41.7 M133.8 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.8610.37654.4 K
Pretty Stable
Dividend Yield4.0E-44.0E-46.0E-4
Slightly volatile
Days Sales Outstanding12571.83139
Very volatile
Average Payables6.3 MMM
Slightly volatile
Stock Based Compensation To Revenue0.150.1623111
Pretty Stable
Sales General And Administrative To Revenue0.550.5808168
Pretty Stable
Average Inventory3.3 M6.1 M4.7 M
Slightly volatile
Research And Ddevelopement To Revenue0.310.3261458
Pretty Stable
Cash Per Share1.461.5322743
Slightly volatile
Capex To Operating Cash Flow1.0E-41.0E-40.0025
Slightly volatile
Intangibles To Total Assets0.00230.00240.0672
Slightly volatile
Net Debt To EBITDA1.090.84831.1291
Slightly volatile
Current Ratio5.755.91856.0498
Slightly volatile
Receivables Turnover6.355.264.1586
Very volatile
Graham Number1.431.5074.2 K
Slightly volatile
Average Receivables127.6 K155.2 K121 K
Pretty Stable
Revenue Per Share1.561.64632.4264
Slightly volatile
Interest Debt Per Share0.760.80430.4596
Very volatile
Debt To Assets0.290.30820.2023
Pretty Stable
Ebt Per Ebit1.080.63310.9723
Very volatile
Quick Ratio5.645.05.7115
Slightly volatile
Dividend Paid And Capex Coverage Ratio11.9 K11.3 K6.3 K
Pretty Stable
Net Income Per E B T1.030.97011.0009
Slightly volatile
Cash Ratio1.641.734.386
Slightly volatile
Days Of Sales Outstanding12571.83139
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.0205
Slightly volatile
Fixed Asset Turnover30.1228.68788.6871
Very volatile
Capital Expenditure Coverage Ratio11.9 K11.3 K6.3 K
Pretty Stable
Debt Ratio0.290.30820.2023
Pretty Stable
Price Sales Ratio9.8610.37654.4 K
Pretty Stable
Asset Turnover0.40.7090.0799
Slightly volatile

TG Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.5 B2.4 B1.2 B
Slightly volatile

TGTX Fundamental Market Drivers

Forward Price Earnings140.8451
Cash And Short Term Investments217.5 M

TGTX Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About TG Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include TG Therapeutics income statement, its balance sheet, and the statement of cash flows. TG Therapeutics investors use historical funamental indicators, such as TG Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although TG Therapeutics investors may use each financial statement separately, they are all related. The changes in TG Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on TG Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on TG Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue300 K285 K
Total Revenue233.7 M245.3 M
Cost Of Revenue14.6 M22 M
Stock Based Compensation To Revenue 0.16  0.15 
Sales General And Administrative To Revenue 0.58  0.55 
Research And Ddevelopement To Revenue 0.33  0.31 
Capex To Revenue(0.01)(0.01)
Revenue Per Share 1.65  1.56 
Ebit Per Revenue 0.09  0.09 

Currently Active Assets on Macroaxis

When determining whether TG Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of TG Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tg Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tg Therapeutics Stock:
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for TGTX Stock analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Money Managers
Screen money managers from public funds and ETFs managed around the world
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is TG Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TG Therapeutics. If investors know TGTX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TG Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.09
Revenue Per Share
1.646
Quarterly Revenue Growth
548.638
Return On Assets
0.0493
Return On Equity
0.1157
The market value of TG Therapeutics is measured differently than its book value, which is the value of TGTX that is recorded on the company's balance sheet. Investors also form their own opinion of TG Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is TG Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TG Therapeutics' market value can be influenced by many factors that don't directly affect TG Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TG Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if TG Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TG Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.